Genome-wide mechanisms of Smad binding

Oncogene

Volumn 32, Issue 13, 2013, Pages 1609-1615

  Morikawa, M ^a,b   Koinuma, D ^b   Miyazono, K ^a,b   Heldin, C H ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

BMP; ChIP chip; ChIP sequencing; Smad; TGF

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BINDING SITE; CANCER GROWTH; GENE CONTROL; GENETIC ASSOCIATION; GROWTH; HISTONE MODIFICATION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME; HUMANS; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; SMAD PROTEINS;

EID: 84875898377     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.191     Document Type: Review

References (81)

1. Massague J. TGFbeta in cancer. Cell 2008; 134: 215-230.
2. Ikushima H, Miyazono K. TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
3. Feng XH, Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693.
4. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58.
5. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 2010; 147: 781-792.
6. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-8623.
7. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci 2005; 118: 3573-3584.
8. Miyazono K, Ehata S, Koinuma D. Tumor-promoting functions of transforming growth factor-beta in progression of cancer. Ups J Med Sci 2012; 117: 143-152.
9. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009; 5: 504-514.
10. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-327.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
12. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446.
13. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
14. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
15. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
16. Park PJ. ChIP-seq: Advantages and challenges of a maturing technology. Nat Rev Genet 2009; 10: 669-680.
17. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNA-seq studies. Nat Methods 2009; 6: S22-S32.
18. Mullen AC, Orlando DA, Newman JJ, Loven J, Kumar RM, Bilodeau S et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 2011; 147: 565-576.
19. Trompouki E, Bowman TV, Lawton LN, Fan ZP, Wu DC, DiBiase A et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 2011; 147: 577-589.
20. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008; 133: 1106-1117.
21. Kennedy BA, Deatherage DE, Gu F, Tang B, Chan MW, Nephew KP et al. ChIP-seq defined genome-wide map of TGFbeta/SMAD4 targets: Implications with clinical outcome of ovarian cancer. PLoS One 2011; 6: E22606.
22. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
23. Zhang Y, Feng XH, Smad Derynck R. and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998; 394: 909-913.
24. Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, Sunamura M et al. Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling. Mol Cell Biol 2009; 29: 172-186.
25. Koinuma D, Tsutsumi S, Kamimura N, Imamura T, Aburatani H, Miyazono K. Promoter-wide analysis of Smad4 binding sites in human epithelial cells. Cancer Sci 2009; 100: 2133-2142.
26. Yoon SJ, Wills AE, Chuong E, Gupta R, HEB Baker JC. and E2A function as SMAD/FOXH1 cofactors. Genes Dev 2011; 25: 1654-1661.
27. Ikushima H, Komuro A, Isogaya K, Shinozaki M, Hellman U, Miyazawa K et al. An Idlike molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling. EMBO J 2008; 27: 2955-2965.
28. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006; 10: 203-214.
29. Silvestri C, Narimatsu M, von Both I, Liu Y, Tan NB, Izzi L et al. Genome-wide identification of Smad/Foxh1 targets reveals a role for Foxh1 in retinoic acid regulation and forebrain development. Dev Cell 2008; 14: 411-423.
30. Kim SW, Yoon SJ, Chuong E, Oyolu C, Wills AE, Gupta R et al. Chromatin and transcriptional signatures for Nodal signaling during endoderm formation in hESCs. Dev Biol 2011; 357: 492-504.
31. Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A et al. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci USA 2006; 103: 12747-12752.
32. Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 1998; 12: 2114-2119.
33. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 1998; 12: 2153-2163.
34. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 2003; 11: 915-926.
35. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010; 18: 655-668.
36. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009; 139: 757-769.
37. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 2007; 25: 441-454.
38. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997; 389: 618-622.
39. Aubin J, Davy A, Soriano P. In vivo convergence of BMP and MAPK signaling pathways: Impact of differential Smad1 phosphorylation on development and homeostasis. Genes Dev 2004; 18: 1482-1494.
40. Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 2007; 131: 980-993.
41. Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massague J et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 2011; 25: 1275-1288.
42. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GHA. SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999; 400: 687-693.
43. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 2005; 386: 461-470.
44. Gao S, Alarcon C, Sapkota G, Rahman S, Chen PY, Goerner N et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell 2009; 36: 457-468.
45. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136: 123-135.
46. Inui M, Manfrin A, Mamidi A, Martello G, Morsut L, Soligo S et al. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol 2011; 13: 1368-1375.
47. Lonn P, van der Heide LP, Dahl M, Hellman U, Heldin CH, Moustakas A. PARP-1 attenuates Smad-mediated transcription. Mol Cell 2010; 40: 521-532.
48. Huang D, Wang Y, Wang L, Zhang F, Deng S, Wang R et al. Poly(ADP-ribose) polymerase 1 is indispensable for transforming growth factor-beta Induced Smad3 activation in vascular smooth muscle cell. PLoS One 2011; 6: E27123.
49. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-617.
50. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem 1999; 274: 703-709.
51. Chai J, Wu JW, Yan N, Massague J, Pavletich NP, Shi Y. Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA binding. J Biol Chem2003; 278: 20327-20331.
52. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling. Cell 1998; 94: 585-594.
53. BabuRajendran N, Palasingam P, Narasimhan K, Sun W, Prabhakar S, Jauch R et al. Structure of Smad1 MH1/DNA complex reveals distinctive rearrangements of BMP and TGF-beta effectors. Nucleic Acids Res 2010; 38: 3477-3488.
54. Lee KL, Lim SK, Orlov YL, Yit le Y, Yang H, Ang LT et al. Graded Nodal/Activin signaling titrates conversion of quantitative phospho-Smad2 levels into qualitative embryonic stem cell fate decisions. PLoS Genet 2011; 7: E1002130.
55. Zhang Y, Handley D, Kaplan T, Yu H, Bais AS, Richards T et al. High throughput determination of TGFbeta1/SMAD3 targets in A549 lung epithelial cells. PLoS One 2011; 6: E20319.
56. Kim J, Johnson K, Chen HJ, Carroll S, Laughon A. Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 1997; 388: 304-308.
57. Morikawa M, Koinuma D, Tsutsumi S, Vasilaki E, Kanki Y, Heldin CH et al. ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res 2011; 39: 8712-8727.
58. Mizutani A, Koinuma D, Tsutsumi S, Kamimura N, Morikawa M, Suzuki HI et al. Cell type-specific target selection by combinatorial binding of Smad2/3 proteins and hepatocyte nuclear factor 4alpha in HepG2 cells. J Biol Chem2011; 286: 29848-29860.
59. Cao Y, Yao Z, Sarkar D, Lawrence M, Sanchez GJ, Parker MH et al. Genome-wide MyoD binding in skeletal muscle cells: A potential for broad cellular reprogramming. Dev Cell 2010; 18: 662-674.
60. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
61. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 2011; 43: 264-268.
62. Zaret KS, Carroll JS. Pioneer transcription factors: Establishing competence for gene expression. Genes Dev 2011; 25: 2227-2241.
63. Harvey SA, Smith JC. Visualisation and quantification of morphogen gradient formation in the zebrafish. PLoS Biol 2009; 7: E1000101.
64. Green JB, New HV, Smith JC. Responses of embryonic Xenopus cells to activin and FGF are separated by multiple dose thresholds and correspond to distinct axes of the mesoderm. Cell 1992; 71: 731-739.
65. Fei T, Xia K, Li Z, Zhou B, Zhu S, Chen H et al. Genome-wide mapping of SMAD target genes reveals the role of BMP signaling in embryonic stem cell fate determination. Genome Res 2010; 20: 36-44.
66. Kaneda A, Fujita T, Anai M, Yamamoto S, Nagae G, Morikawa M et al. Activation of Bmp2-Smad1 signal and its regulation by coordinated alteration of H3K27 trimethylation in Ras-induced senescence. PLoS Genet 2011; 7: E1002359.
67. Akizu N, Estaras C, Guerrero L, Marti E, Martinez-Balbas MA. H3K27me3 regulates BMP activity in developing spinal cord. Development 2010; 137: 2915-2925.
68. Dahle O, Kumar A, Kuehn MR. Nodal signaling recruits the histone demethylase Jmjd3 to counteract polycomb-mediated repression at target genes. Sci Signal 2010; 3: Ra48.
69. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 2006; 125: 929-941.
70. Xi Q, Wang Z, Zaromytidou AI, Zhang XH, Chow-Tsang LF, Liu JX et al. A poised chromatin platform for TGF-beta access to master regulators. Cell 2011; 147: 1511-1524.
71. Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 2011; 43: 85-96.
72. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 2005; 121: 87-99.
73. Farnham PJ. Insights from genomic profiling of transcription factors. Nat Rev Genet 2009; 10: 605-616.
74. Landry JR, Bonadies N, Kinston S, Knezevic K, Wilson NK, Oram SH et al. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors. Blood 2009; 113: 5783-5792.
75. Pimanda JE, Donaldson IJ, de Bruijn MF, Kinston S, Knezevic K, Huckle L et al. The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci USA 2007; 104: 840-845.
76. Simonis M, Kooren J, de Laat W. An evaluation of 3C-based methods to capture DNA interactions. Nat Methods 2007; 4: 895-901.
77. Penn BH, Bergstrom DA, Dilworth FJ, Bengal E, Tapscott SJ. A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev 2004; 18: 2348-2353.
78. Yokoyama S, Ito Y, Ueno-Kudoh H, Shimizu H, Uchibe K, Albini S et al. A systems approach reveals that the myogenesis genome network is regulated by the transcriptional repressor RP58. Dev Cell 2009; 17: 836-848.
79. van de Vijver MJ, He YD, van Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
80. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008; 47: 2059-2067.
81. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-765.